尿苷5'-三磷酸酯
尿苷5'-三磷酸酯 性质
| 密度 | 2.106±0.06 g/cm3(Predicted) |
|---|---|
| 闪点 | 113 °C |
| 储存条件 | Sealed in dry,2-8°C |
| 形态 | 液体 |
| 酸度系数(pKa) | pK1:7.58 (25°C) |
| 颜色 | 无色 |
| 水溶解性 | Water : ≥ 150 mg/mL (309.83 mM) |
| CAS 数据库 | 63-39-8(CAS DataBase Reference) |
| EPA化学物质信息 | Uridine 5'-(tetrahydrogen triphosphate) (63-39-8) |
尿苷5'-三磷酸酯 用途与合成方法
|
Human Endogenous Metabolite
|
Uridine triphosphate treatment induces Schwannoma cell migration through activation of P2Y2 receptors and through the increase of extracellular matrix metalloproteinase-2 (MMP-2) activation and expression. Uridine triphosphate-induced proliferation is mediated by protein kinase D, Src-family tyrosine kinase, Ca/calmodulin-dependent protein kinase II, phosphatidylinositol 3-kinase (PI3K), Akt, and phospholipase D. Uridine triphosphate increases phosphorylation of Akt through protein kinase C, Src-family tyrosine kinase, Ca/calmodulin-dependent protein kinase II, and PI3K.
Uridine triphosphate reduces mitochondrial calcium levels following hypoxia. Early or late uridine triphosphate preconditioning is effective to reduce infarct size and superior myocardial function. Uridine triphosphate treatment increases the number of monocytes and macrophages infiltrating the pouch and up-regulates the gene expression of IL-4 and IL-13 in the regional lymph nodes.
尿苷5'-三磷酸酯 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-107372 | 5 mg | 375 | ||
| 2024-01-25 | HY-107372 | 尿苷5'-三磷酸酯 | 63-39-8 | 10mg | 600 |
